EUVIMEDEUVIMED entdecken
EditorialKommentar

Risankizumab versus apremilast in the era of skin clearance

Emma Veysey

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad328 ↗

Kurz gefasst

Editorial in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Emma Veysey. Beteiligte Einrichtung: Dermatology Department, St Vincent's Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Psoriasis. Die Arbeit nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The evolution of highly effective targeted therapies has redefined treatment expectations for individuals with moderate-to-severe psoriasis and their clinicians. Near or complete skin clearance is now a realistic goal; however, access to these agents is restricted by cost. Risankizumab, a subcutaneously administered monoclonal antibody interleukin-23p19 inhibitor, has demonstrated high efficacy and a favourable side-effect profile.1,2 Apremilast is a small-molecule phosphodiesterase 4 inhibitor and is considered a useful alternative to conventional systemic therapy when an oral treatment is preferred.3 It has the advantage of an excellent safety profile and requires no blood test monitoring. To date, network meta-analyses have relied on indirect data to compare the efficacy for these two agents. Of these analyses, the living Psoriasis Cochrane Review concluded that risankizumab is 27.67 [95% confidence interval (CI) 22.86–33.49)] times more likely than placebo to achieve a 90% reduction in Psoriasis Area and Severity Index (PASI 90) at 16 weeks vs. 7.30 (95% CI 4.26–12.51) times as likely for apremilast. In addition, a league table of relative, induction phase effectiveness places apremilast third from the bottom, ahead of acitretin and fumaric acid esters (FAEs), and risankizumab third from the top, behind infliximab and ixekizumab, with 13 agents in between.4

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalPsoriasisAdultHumansSkinThalidomide

Substanzen

Antibodies, MonoclonalrisankizumabapremilastThalidomide

Autor:innen und Institutionen

  • Dermatology Department, St Vincent's Hospital, Melbourne, Australia.

Zitieren

APA

Veysey, E. (2023). Risankizumab versus apremilast in the era of skin clearance. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad328

Vancouver

Veysey E. Risankizumab versus apremilast in the era of skin clearance. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad328

BibTeX
@article{Veysey2023,
  author = {Veysey, Emma},
  title = {Risankizumab versus apremilast in the era of skin clearance},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad328}
}
Kostenlos starten →